Volume 7 Issue 1, Jan 2022

ISSN: 2095-9907 

EISSN: 2059-23635 

2023 impact factor 40.8 

 (Clarivate Analytics, 2024)

Volume 7 Issue 1, Jan 2022:
Review Article
An overview of kinase downregulators and recent advances in discovery approaches
Beilei Wang,Hong Wu,Chen Hu,Haizhen Wang,Jing Liu,Wenchao Wang &…Qingsong Liu  ORCID: orcid.org/0000-0002-7829-2547 
Since the clinical approval of imatinib, the discovery of protein kinase downregulators entered a prosperous age. However, challenges still exist in the discovery of kinase downregulator drugs, such as the high failure rate during development, side effects, and drug-resistance problems. With the progress made through multidisciplinary efforts, an increasing number of new approaches have been applied to solve the above problems during the discovery process of kinase downregulators. In terms of in vitro and in vivo drug evaluation, progress was also made in cellular and animal model platforms for better and more clinically relevant drug assessment. Here, we review the advances in drug design strategies, drug property evaluation technologies, and efficacy evaluation models and technologies. Finally, we discuss the challenges and perspectives in the development of kinase downregulator drugs.